Triethyl-2-phosphonopropionate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Triethyl-2-phosphonopropionate
• 英文别名: 3,3-diethyl-2-phosphonopentanoate
• 化学式: C9H18O5P-
• 分子量: 237.21
• InChiKey: LQLCRMCSHBOJRE-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  97.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-cyclopropyl-2-(2,6-dichloro-pyridin-4-yl)-3H-imidazole-4-carbaldehyde 、 Triethyl-2-phosphonopropionate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 在 二氯甲烷 、 Sodium sulfate-III 、 silica gel 作用下， 以 乙腈 、 水 为溶剂， 以to isolate the title compound (1.66 g, 86%)的产率得到3-[3-Cyclopropyl-2-(2,6-dichloro-pyridin-4-yl)-3H-imidazol-4-yl]-2-methyl-acrylic acid ethyl ester
  参考文献：
  名称：

  ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及公式I的新化合物，含有该化合物的药物配方以及在预防和/或治疗mGluR5受体介导的疾病中使用该化合物的方法。

  公开号：

  US20070293545A1

文献信息

• Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：Edwards Louise

  公开号：US20050272779A1

  公开（公告）日：2005-12-08

  The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

  本发明涉及公式I的新化合物，包含该化合物的制药组合物，以及在预防和/或治疗mGluR5受体介导的疾病中使用该化合物的方法。
• Peroxisome proliferator activated receptor agonists
  申请人：Gibson Ann Tracey

  公开号：US20050020652A1

  公开（公告）日：2005-01-27

  The present invention is directed to compounds represented by the following structural Formula (I), (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C 1 -C 8 alkyl, aryl-C 0-4 -alkyl, heteroaryl-C 0-4 -alkyl, C 6 cycloalkylaryl-C 0-2 -alkyl, and —CH 2 —C(O)—R17-R18, wherein R17 is O or NH and R18 is optionally substituted benzyl; (b) R2 is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkenyl, aryl-C 0-4 -alkyl, heteroaryl-C 0-4 -alkyl, C 1 -C 4 alkyl sulfonamide, C 1 -C 4 alkyl amide, OR10 and C 3 -C 6 cycloalkyl; (c) W is O or S; (d) X is an optionally substituted C 1 -C 5 alkylene linker wherein one carbon atom of the linker may optionally be replaced with O, NH, S, and optionally two carbons together may form a double bond; (e) Y is selected from the group consisting of C, O, S, NH and a single bond; and (f) E is selected from the group consisting of C(R3) (R4)A, A, and a substituted or unsubstituted group selected from the group consisting of (CH 2 )n COOR19.

  本发明涉及以下结构式(I)所表示的化合物，其中：(a) R1选自氢、C1-C8烷基、芳基-C0-4-烷基、杂芳基-C0-4-烷基、C6环烷基芳基-C0-2-烷基和—CH2—C(O)—R17-R18的取代或未取代基团，其中R17为O或NH，R18为可选的取代苯基；(b) R2选自C1-C6烷基、C1-C6烯基、芳基-C0-4-烷基、杂芳基-C0-4-烷基、C1-C4烷基磺酰胺、C1-C4烷基酰胺、OR10和C3-C6环烷基；(c) W为O或S；(d) X为可选取代的C1-C5烷基链，其中链的一个碳原子可选地被O、NH、S替换，可选地两个碳原子可以形成双键；(e) Y选自C、O、S、NH和单键；(f) E选自C(R3)(R4)A、A和取代或未取代的( )nCOOR19基团。
• Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
  申请人：Vasudevan Jayasree

  公开号：US20050187298A1

  公开（公告）日：2005-08-25

  The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

  本发明提供了治疗具有视黄醇响应性疾病的个体的方法。在一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26B抑制剂，该选择性CYP26B抑制剂相对于CYP26A具有至少10倍的选择性。在另一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26A抑制剂，该选择性CYP26A抑制剂具有在规范中列出的化学式。本发明还提供了筛选方法，用于识别选择性CYP26A抑制剂或选择性CYP26B抑制剂。
• Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl)
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US06057369A1

  公开（公告）日：2000-05-02

  This invention is directed to compounds of formula I: ##STR1## wherein the variables are as described herein. Compounds within the scope of the present invention possess useful properties, more particularly pharmaceutical properties. They are especially useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. Compounds within the scope of the present invention may also inhibit an MMP, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting MMPs, such disease states involve tissue breakdown and those associated with a physiologically detrimental excess of TNF. The present invention is therefore also directed to the pharmaceutical use of the compounds, pharmaceutical compositions containing the compounds, intermediates leading thereto and methods for the preparation of the compounds and their intermediates.

  本发明涉及式I的化合物：##STR1## 其中变量如本文所述。本发明所涵盖的化合物具有有用的性质，特别是药物性质。它们在治疗患有与生理有害的肿瘤坏死因子（TNF）过度相关的疾病状态的患者中抑制TNF的产生或生理效应特别有用。本发明所涵盖的化合物还抑制环磷酸腺苷磷酸二酯酶，并且在治疗与抑制环磷酸腺苷磷酸二酯酶有关的病理条件的疾病状态中有用，这些疾病状态包括炎症和自身免疫性疾病，特别是第四型环磷酸腺苷磷酸二酯酶。本发明所涵盖的化合物还可能抑制MMP，并且在治疗与抑制MMP有关的病理条件的疾病状态中有用，这些疾病状态涉及组织分解和与TNF过度有害相关的疾病状态。因此，本发明还涉及化合物的药物用途、含有该化合物的药物组合物、导致其中间体的中间体以及制备该化合物及其中间体的方法。
• Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
  申请人：Allergan, Inc.

  公开号：US07226951B2

  公开（公告）日：2007-06-05

  Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.

  规范书中提供的化学式1到17的化合物可以特异性地抑制细胞色素P450RAI-1酶或细胞色素P450RAI-2酶。